Healthcare NSE: CIPLA

Cipla Financial Statements, P/E Ratio & ROE Valuation

Cipla (CIPLA) — Drug Manufacturers - Specialty & Generic

₹1,477.00 INR

▲ ₹18.20 (+1.25%)

Overview Share Price Financials & P/E Dividends Shareholding Peer Comparison

Cipla Financial Statements & Valuation Multiples

✨ Financials & Valuation Analysis

Cipla commands a premium valuation with a P/E of 35.3942, supported by high market dominance and profitability expectations.

P/E Ratio (TTM) 35.3942

Forward P/E 23.27007

Price-to-Book (P/B) 3.4650784

Return on Equity (ROE) N/A

Profit Margin 12.01%

Operating Margin 12.55%

EPS (TTM) ₹41.73

Enterprise Value ₹1.10 Lakh Cr

Financial Health & Profitability Breakdown for Cipla

A comprehensive review of Cipla reveals an ROE of N/A and operating profitability margins of 12.55%. Cipla maintains high capital efficiency with an ROE of null% and operating margins of 12.55%, demonstrating robust cash generation capabilities.

Evaluating valuation metrics, Cipla maintains a Price-to-Earnings ratio of 35.3942 and a Price-to-Book multiple of 3.4650784. These valuation metrics, combined with an Enterprise Value of ₹1.10 Lakh Cr, provide essential indicators for fundamentally driven stock selection in India's Healthcare sector.

Frequently Asked Questions

What is Cipla P/E ratio and Price-to-Book (P/B) ratio?

Cipla trades at a trailing P/E of 35.3942, a Forward P/E of 23.27007, and a P/B ratio of 3.4650784.

What is Cipla Return on Equity (ROE)?

Cipla reports a Return on Equity (ROE) of N/A, reflecting shareholder capital efficiency.

What are Cipla profit margin and operating margin?

Cipla maintains a net profit margin of 12.01% and an operating margin of 12.55%.

What is Cipla Enterprise Value and EBITDA multiplier?

Cipla has an Enterprise Value of ₹1.10 Lakh Cr and reported earnings per share (TTM EPS) of ₹41.73.

Explore Similar Healthcare Stocks

Explore Categories:

Technology Stocks Banking Stocks Nifty 50 Stocks Dividend Stocks Large Cap Stocks